Futura Medical Share Discussion Threads

[lbo] 27/10/2022 17:40

GSK knew it was a lubricant having placebo effects all along even before it failed phase3. And now with the GTN ‘penile enhancer’ action removed after the phase 3 failure of Med2005/2002. Med3000 has nothing more then one action left. A lubricant with placebo effects when users are led to believe ‘it works’ for ED.



No Goopy ED Gel in GSK’s Futura

[lbo] 27/10/2022 15:58

It has already been admitted the Dermasy vehicle and Voltaren vehicle give similar results! LOL



˜TPR100 gave similar results to the gold standard, Voltarol 2% gel’



The cooling effect of a topically applied product can be evaluated using a validated handheld thermal imaging system. When the gel matrix is destroyed after application to the skin, the bound water and alcohol evaporates and a measurable cooling-effect results. Consumer satisfaction with a topical product is based on subjective criteria such as how the product feels and how it is perceived on the skin. Therefore, appropriate questionnaires are of major importance for cosmetic products to assess the subjective perception not only of soothing and cooling effects but also of moistur- izing properties and fragrance.



A key element of Futura Medicals strategy is to reduce development risk through using well characterised existing agents that are reformulated with its proprietary DermaSys technology to create new products. This means intellectual property protection is limited to use patents for the individual products and umbrella patents for the technology. There is a risk that some claims will either be challenged in future (eg on the grounds of non-obviousness or existence of prior art) and/or that another technology may be employed to achieve a similar effect

[lbo] 27/10/2022 15:56

The problem is all the so called evidence that ‘it works’ is all deficient. There is no evidence that Med3000 itself is having any effect beyond a placebo in any adequately controlled study. All the deficient evidence proves is that placebos have effects in ED. This was already known from the oral PDE5I studies. But the bigger problem is if Med3000 placebo gel does ‘work’ then any cooling lubricant/arousal gel will also be able to replicate the same effect! Futura haven’t even done a simple comparison study with a standard cooling lubricant or arousal gel. So they can’t even claim Med3000 is any better then using them for rubbing, cooling and placebo effect! Futura do not even have a patent that can prevent Reckitt from making similar claims about its arousal gels/lubricants and even using similar alcohol and water vehicle gels to make the same evaporative cooling claims as Dermasys.

[mikethebike4] 27/10/2022 14:42

The problem for LBO is that it does work and very well judging by the results

All these authorities that LBO drags up are all part of the self-appointed, learned brotherhood all of whom know each other, went to the same schools & colleges etc. etc. and cannot believe that any other sort of person not in the fraternity could develop a substance that works

Ignore him he is annoyed that he lost a packet ages ago, playing the market unsuccessfully

[c140] 27/10/2022 12:58

Can a person be really swindled If any product actually works for them? Eroxon isn't the silver bullet for ED but it's positive news - regardless of mechanism, for those that it does make a difference for. Good luck to them.

[lbo] 27/10/2022 12:55

Really Joe? LOLJoeStalin - 30 Sep 2019 - 10:07:37 - 5937 of 10774FUTURA a winner for 2015 - says it all!JoeStalin - 18 Jul 2018 - 09:00:46 - 4354 of 10775'jam tomorrow' is a very easy promise to make.JoeStalin - 22 Jun 2018 - 14:12:24 - 4288 of 10775What's another year after all?At FUM, time is measured in decades.JoeStalin - 25 Apr 2018 - 16:07:34 - 4147 of 10775There seems to be an unlimited number of ways of saying "Jam tomorrow".JoeStalin - 21 Mar 2018 - 13:50:44 - 3985 of 10775A lifestyle company, but not for the shareholders.

[joestalin] 27/10/2022 12:44

LBO seems to post a negative riposte within 10 minutes of anybody making a comment.

This is a classic case of OCD. Very sad.

[mikethebike4] 27/10/2022 12:33

C140

Different product !!!

[lbo] 27/10/2022 12:14

Really Mike!? You have repeatedly and openly said not to believe anything this company claims and they always fail to deliver when they say all is ‘rosy’! LOL


mikethebike4 - 11 Apr 2018 - 14:35:10 - 4072 of 11141

Having had similar waffling, 'smoke-screen' answers from Mr Barder over the years which have turned out to end in exactly nothing I am loathe to give any credence to virtually everything he says

mikethebike4 - 11 Apr 2018 - 15:58:28 - 4091 of 11141

Company is massively over valued if you go by 'concrete' results !

mikethebike4 - 11 Apr 2018 - 15:14:56 - 4082 of 11141

I only try and bring some sort of balance into the equation to help the gullible not get carried away with fanciful future projections.
I would like nothing better than to be proved wrong about Mr Barder (our CEO since 2001) and to sale away into the sunset grasping 5 times as many £s in my fist as I paid for the shares
Unfortunately for people like J7J, Mr Barder has been through this advisors process before - with CSD500 - and look where we've got in 17 years - sales of the product did not even equal the money we paid him to be our CEO for 2017 !

mikethebike4 - 06 Dec 2017 - 10:32:27 - 3468 of 10591

"A couple of decent deals and will be back off to the races."
Do you have any idea of how long shareholders have been using these words

mikethebike4 - 23 Mar 2017 - 09:52:33 - 2560 of 10591

As someone who has been invested for many years and who attended an AGM years ago and complained to Barder about the very slow progress, I am very frustrated.
All the time the Board are drawing good salaries off the backs of shareholders money they have very little incentive to get off their backsides and get 'selling' - thats what running a company is all about at the end of the day!

mikethebike4 - 24 Feb 2020 - 09:11:58 - 7290 of 9713

why should it be any different this time when you've still got the same useless lot running the show

mikethebike4 - 07 Jan 2019 - 11:22:52 - 4692 of 9641

I repeat I very much hope you are right - no one would be happier than me if you are - however I stupidly (in hindsight) bought in when everything looked really rosy - we were told there were loads of 'distributors' all 'champing at the bit to get selling a wonderful industry disruptive product (which it still is incidentally) once the 2 year shelf-life problem was fixed. This was despite the fact that the Holland/Belgium distributor was quite happy and successful selling them with the original 18 months shelf-life
And where are we now years later - one tiny distributor from which Futura receives a total sales income only just about covering Mr Barders employment remuneration
I just hope this MED/TPR situation is not just a repeat of CSD. As to why I don't just sell up, well my shareholding is worth such a tiny proportion of what I paid for it I might just as well hang on in the hope that new shareholders getting in now are luckier than I was and I can get some of my money back - I think what we need is Mr Barders retirement - that should give the share price a kick

[lbo] 27/10/2022 11:51

For many, whether or not placebo use is ethical depends partly on whether patients are being deceived and whether there is a known better treatment. A clinician who doesnt deceive a patient, and who provides a placebo for something for which there is no known treatment, such as irritable bowel syndrome, might be ethically OK, says Jeremy Howick, of the Department of Primary Health Care Sciences, at the University of Oxford, and lead author of the Plos One study. But there is no evidence that this company is enhancing care. What they've been doing is completely unethical


Placebo-nomics: how bad was what Nurofen did? (Or how bad will the courts see what MED3000 do if they claim they are claiming to be having any effect beyond a placebo or even any cooling lubricant/arousal gels already on the market yet cannot substantiate that claim)

Australian courts have ordered the makers of the brand to stop repackaging identical painkillers for different pains where does marketing end and deception begin?

Lies come in a wide range of ethical shapes and sizes. There are white ones, diplomatic ones, and there are mean, self-serving ones. Apparently there are even nice, Christmassy ones.

The Australian federal court yesterday ordered the drug giant Reckitt Benckiser to stop selling identical products marketed as specific Nurofen varieties for back pain, period pain, migraine pain and tension headaches. The company admitted the drugs sold in different coloured packets all contained the same active ingredient: 342mg of ibuprofen lysine. It also sold them at almost twice the price of Nurofen standard ibuprofen products.

Whether this constitutes deception or just marketing is probably one for the lawyers to argue over. Whatever its called, such practices might appear to fall pretty unequivocally towards the self-serving whopper end of the scale

[lbo] 27/10/2022 11:48

So you wouldn’t care if you were swindled into buying a placebo? Especially one just made of Alcohol, water and glycol and when more appropriate treatments also exist tor the real underlying causes of the ED. But the real problem is anyone including Reckitt can now sell their own placebo gel/lubricant for ED and report MED3000 to the ASA and FTC if it doesn’t give clear disclaimers MED3000 has shown no effect beyond a placebo in any adequately controlled study.

Even the market forecasts know all Futura have done is paid for the research to allow Reckitt also claim its class 2 medical device lubricants/arousal gels are also placebo treatments for Psychogenic ED!




Reckitt Benckiser was the defined leader and the ultimate four Personal lubricant vendors with leading brands such as Durex Play and K-Y Jelly.

KEY GROWTH FACTORS

Increasing prevalence of erectile dysfunction

9 Market Growth Enablers
9.1 Increasing Prevalence of Erectile Dysfunction

[c140] 27/10/2022 11:03

Having recently become a small shareholder here, one question to me from reading several posts is, will sufferers of ED actually care about clinical trials, ingredients, how it works etc if it works for them? Isn't the answer no - they won't care. Haven't the company also acknowledged that the product will not be for universal use - people with other underlying conditions? Hopefully 2023 will be rewarding.

[lbo] 26/10/2022 15:27

“It’s all in the American Urological Association [AUA] guidelines.

‘The therapies have not been validated’

‘I recommend what we have as standard of care, which includes pills, injections, penile prosthesis, and vacuum devices that we know work. Other therapies have not been included in the standard of care yet’

The first line therapy recommended in the General practice guidelines on ED is oral PDE5I drugs. Which would be based on all the available objective evidence. It would not be based solely on a rampers subjective and unqualified personal view. Or if a person just own shares in a company with a placebo gel alternative and who may have a vested interest and biased opinion.



First-line therapy

For most men with ongoing confirmed ED, first-line treatment will be a phosphodiesterase-5 inhibitor (PDE5I).



Phosphodiesterase 5 (PDE5) inhibitors (sildenafil, tadalafil, vardenafil) are recommended as first-line therapy. With established safety profiles, these drugs are well tolerated and effective

GPC prescribing lead Dr Andrew Green:

'There is no doubt that sildenafil is a safe and effective drug’

[lbo] 26/10/2022 13:15

There is no API in Med3000. If you are claiming there is then it cannot be a medical device! LOL

Futura is not making the false claims you are now making on ADVFN. In MED3000. Dermasys in Med3000 is delivering no API as it contains no API. In Med2005/2002 Dermasys was delvering GTN but that failed the phase 3 study so they were just left with the placebo Med3000 gel which is Dermasys on its own and delivers nothing but a cooling sensation!



PLO = Placebo (identical gel to MED2005 but without the active pharmaceutical ingredient glyceryl trinitrate)



After Phase III Failure, UK Firm Pushes Placebo to Treat Erectile Dysfunction